Highlights

  • CSL reported FY26 Operating Revenue of US$15.8 billion and underlying NPATA attributable to shareholders of US$3.1 billion.
  • The statutory result moved to a US$2.579 billion loss attributable to shareholders after restructuring and Impairment expenses.
  • Cash flow from operations was US$3.512 billion, supporting dividends and Capital management during the reset period.
  • CSL Behring remained the largest Business by revenue, while CSL Vifor faced pressure from generic competition and regulatory developments.
  • FY27 priorities centre on efficiency, commercial execution, product Demand and managing Vifor-related pressures.

CSL Limited (ASX:CSL) is a global biopharma company focused on plasma-derived therapies, vaccines and medicines for serious and complex diseases. Its FY26 result shows a business undergoing a broad reset: underlying Earnings remained profitable, but restructuring and impairment charges moved the statutory result into loss. The key issue for FY27 is how operational improvements, product demand and portfolio changes translate into reported earnings.

FY26 Earnings Show a Wide Statutory and Underlying Gap

For the year ended 30 June 2026, CSL (ASX:CSL) reported total operating revenue of US$15.797 billion. Underlying NPATA attributable to shareholders was US$3.098 billion, down 2% on a constant-currency basis. By contrast, the statutory net loss attributable to CSL shareholders was US$2.579 billion. The difference reflects significant non-recurring items, including restructuring and impairment expenses, rather than a collapse in the group’s underlying operating cash generation.

The Annual Report recorded restructuring and impairment expenses of US$7.923 billion before tax. Impairments were reported at US$7.1 billion, while Research and Development expense was US$1.223 billion. Cash Flow from operations reached US$3.512 billion. These figures illustrate why CSL’s underlying and statutory measures need to be read together: one reflects ongoing operating performance, while the other captures the cost of reassessing Assets and reshaping the business.

Business Mix Keeps Behring at the Centre

CSL Behring generated US$11.387 billion of FY26 revenue and remained the group’s largest business. It continues to focus on plasma-derived and specialty therapies, with demand for immunoglobulin products an important operating factor. CSL Seqirus reported US$2.031 billion of revenue and continued to develop its seasonal and Pandemic influenza portfolio. CSL Vifor reported US$2.379 billion of revenue across iron deficiency and nephrology products.

The divisions face different operating conditions. Behring is focused on improving plasma collection and Manufacturing efficiency, while Seqirus is balancing Vaccine demand with manufacturing and portfolio investment. Vifor enters FY27 with greater pressure from generic competition in iron products and the Withdrawal of TAVNEOS in European Union and European Economic Area markets.

Capital Returns Continue Despite the Reset

CSL (ASX:CSL) maintained total FY26 dividends at US$2.92 per share. The company also completed an A$1 billion share buy-back during FY26 and later announced a further A$1.15 billion buy-back program. These actions were supported by Operating Cash Flow and the group’s balance sheet, although future capital management will continue to depend on cash generation, investment requirements and the progress of the transformation program.

FY27 Focus Shifts to Execution

For FY27, CSL expects Behring to benefit from continuing therapy demand and efficiency initiatives, while manufacturing investment is intended to support capacity and resilience. Seqirus is focused on disciplined execution and differentiated influenza products. Vifor is expected to remain affected by generic competition and the TAVNEOS withdrawal in Europe, while the group continues to pursue patient access and commercial development across its portfolio.

Key Insights

CSL’s FY26 result is best viewed as a reset year in which sizeable accounting charges changed the statutory outcome without eliminating underlying profitability or operating cash flow. The FY27 assessment therefore centres on whether efficiency measures, commercial execution and product demand can improve earnings quality while Vifor-related pressures and restructuring effects are worked through.